| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―May―26 |
Ocular microvascular changes in COVID-19: role of hypoxia, D-dimer, IL-6 and systemic treatment |
Magdalena Kal, Michał Brzdęk, Izabella Karska-Basta, Piotr Rzymski, Antonio Pinna, Mateusz Winiarczyk, Jerzy Mackiewicz, Dominik Odrobina, Dorota Zarębska-Michaluk |
| 2 |
[GO] |
2025―Apr―25 |
Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study |
Renato Ferreira-da-silva, Lurdes Silva, Cristina Costa-Santos, Manuela Morato, Jorge Junqueira Polónia, Inês Ribeiro-Vaz, Manuela Pinto, Marta Pereira, Inês Marques Figueira, Sofia Baptista, Helena Farinha, Fátima Falcão, Ana Mirco, Liliana Calixto, Madalena Melo |
| 3 |
[GO] |
2025―Feb―03 |
Effects of COVID-19 and medication used for treatment and symptom prevention on the antioxidant status |
Laura A. Borba, Getúlio Antonio de Freitas Filho, Taiane de Azevedo Cardoso, Camila O. Arent, Flávia S. Niero, Lucas C. Pedro, Caion A. Rodrigues, Lara R. Cichella, Margarete D. Bagatini, Gabriela Gonçalves de Oliveira, Gilnei Bruno da Silva, Daiane Manica, Zuleide Maria Ignácio, João Quevedo, Luciane B. Ceretta, Gislaine Z. Réus |
| 4 |
[GO] |
2024―Sep―19 |
JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro |
Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti |
| 5 |
[GO] |
2024―Apr―23 |
Role of the RAAS in mediating the pathophysiology of COVID-19 |
Jakub Jasiczek, Adrian Doroszko, Tymoteusz Trocha, Małgorzata Trocha |
| 6 |
[GO] |
2024―Mar―18 |
Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy |
Mahdi Vajdi, Arash Karimi, Shirin Hassanizadeh, Mahdieh Abbasalizad Farhangi, Mohammad Bagherniya, Gholamreza Askari, Basil D. Roufogalis, Neal M. Davies, Amirhossein Sahebkar |
| 7 |
[GO] |
2023―Sep―01 |
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study |
Juan Vicente-Valor, Carmen Rodríguez-González, María Ferris-Villanueva, Esther Chamorro-de-Vega, Rosa Romero-Jiménez, Daniel Gómez-Costas, Sergio Herrero-Bermejo, Francisco Tejerina-Picado, Santiago Osorio-Prendes, Gillen Oarbeascoa-Royuela, Ana Herranz-Alonso, María Sanjurjo-Sáez |
| 8 |
[GO] |
2023―Aug―16 |
Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study |
Marwa O. El-Derany, Diana M. F. Hanna, John Youshia, Enas Elmowafy, Mohamed A. Farag, Samar S. Azab |
| 9 |
[GO] |
2023―Jun―24 |
Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments |
Raj Singh, Parth Malik, Mukesh Kumar, Raman Kumar, Md. Shamshir Alam, Tapan Kumar Mukherjee |
| 10 |
[GO] |
2023―Apr―05 |
Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study |
Małgorzata Siewierska, Mateusz Gajda, Aleksandra Opalska, Michał Brudło, Paweł Krzyściak, Barbara Gryglewska, Anna Różańska, Jadwiga Wójkowska-Mach |
| 11 |
[GO] |
2023―Feb―27 |
Nasal sprays for treating COVID-19: a scientific note |
Vivek P. Chavda, Kajal P. Baviskar, Dixa A. Vaghela, Shilpa S. Raut, Anjali P. Bedse |
| 12 |
[GO] |
2022―Dec―04 |
Platelets in COVID-19 disease: friend, foe, or both? |
Marta Smęda, Ebrahim Hosseinzadeh Maleki, Agnieszka Pełesz, Stefan Chłopicki |
| 13 |
[GO] |
2022―Nov―18 |
Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery |
Raahilah Zahir Essa, Yuan-seng Wu, Kalaivani Batumalaie, Mahendran Sekar, Chit-laa Poh |
| 14 |
[GO] |
2022―Nov―14 |
Health-related quality of life in survivors of severe COVID-19 infection |
Gabriele d’Ettorre, Paolo Vassalini, Vincenzo Coppolelli, Elio Gentilini Cacciola, Letizia Sanitinelli, Luca Maddaloni, Silvia Fabris, Claudio M. Mastroianni, Gabriella d’Ettorre, Giancarlo Ceccarelli |
| 15 |
[GO] |
2022―Nov―07 |
Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials |
Subodh Kumar, Dibyajyoti Saikia, Mangesh Bankar, Manoj Kumar Saurabh, Harminder Singh, Sheshadri Reddy Varikasuvu, Vikas Maharshi |
| 16 |
[GO] |
2022―Oct―10 |
Recent review of COVID-19 management: diagnosis, treatment and vaccination |
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, Sathvika Kamaraj, Aayushi B. Patel, Nikita Sharma, Zhe-Sheng Chen |
| 17 |
[GO] |
2022―Oct―03 |
Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, Piotr Rzymski |
| 18 |
[GO] |
2022―Sep―30 |
Neurological consequences of COVID-19 |
Waldemar Brola, Maciej Wilski |
| 19 |
[GO] |
2022―Sep―27 |
Short-chain fatty acids-microbiota crosstalk in the coronavirus disease (COVID-19) |
Jakub Włodarczyk, Bartłomiej Czerwiński, Jakub Fichna |
| 20 |
[GO] |
2022―Sep―23 |
Correction: Oral antiviral treatments for COVID-19: opportunities and challenges |
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, Mickael Essouma, Aliyu Tijani Jibril, Andrzej Fal, Robert Flisiak, Rangarirai Makuku, Leander Marquez, Kawthar Mohamed, Lamin Ndow, Dorota Zarębska-Michaluk, Nima Rezaei, Piotr Rzymski |
| 21 |
[GO] |
2022―Sep―20 |
Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus |
Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Yogendra Padwad, Vipin Hallan, Sanjay Kumar |
| 22 |
[GO] |
2022―Aug―24 |
Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, Piotr Rzymski |
| 23 |
[GO] |
2022―Aug―23 |
Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study |
Seyed Saman Talebi, Mehran Ghasemi, Maryam Etminani-Esfahani, Younes Mohammadi, Rasool Haddadi |
| 24 |
[GO] |
2022―Aug―23 |
The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic |
Martyna Majchrzak, Marcin Poręba |
| 25 |
[GO] |
2022―Aug―05 |
Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein |
Deisy Segura-Villalobos, Daniela Roa-Velázquez, Dan I. Zavala-Vargas, Jessica G. Filisola-Villaseñor, Jorge Ivan Castillo Arellano, Edgar Morales Ríos, Ricardo Reyes-Chilpa, Claudia González-Espinosa |
| 26 |
[GO] |
2022―Jul―25 |
Oral antiviral treatments for COVID-19: opportunities and challenges |
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, Aliyu Tijani Jibril, Andrzej Fal, Robert Flisiak, Rangarirai Makuku, Leander Marquez, Kawthar Mohamed, Lamin Ndow, Dorota Zarębska-Michaluk, Nima Rezaei, Piotr Rzymski |
| 27 |
[GO] |
2022―Mar―23 |
To aspirate or not to aspirate? Considerations for the COVID-19 vaccines |
Piotr Rzymski, Andrzej Fal |
| 28 |
[GO] |
2022―Jan―15 |
A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2 |
Kasi Pandima Devi, Mahmoud Reza Pourkarim, Marijn Thijssen, Antoni Sureda, Maryam Khayatkashani, Cosmin Andrei Cismaru, Ioana Berindan Neagoe, Solomon Habtemariam, Soha Razmjouei, Hamid Reza Khayat Kashani |
| 29 |
[GO] |
2021―Nov―27 |
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial |
Negar Toroghi, Ladan Abbasian, Anahid Nourian, Effat Davoudi-Monfared, Hossein Khalili, Malihe Hasannezhad, Fereshteh Ghiasvand, Sirous Jafari, Hamid Emadi-Kouchak, Mir Saeed Yekaninejad |
| 30 |
[GO] |
2021―Aug―30 |
COVID-19: potential therapeutics for pediatric patients |
Nour K. Younis, Rana O. Zareef, Ghina Fakhri, Fadi Bitar, Ali H. Eid, Mariam Arabi |
| 31 |
[GO] |
2021―Jul―06 |
The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis |
Krzysztof Marciniec, Artur Beberok, Stanisław Boryczka, Dorota Wrześniok |
| 32 |
[GO] |
2021―Jun―27 |
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention |
Ekta Shirbhate, Jaiprakash Pandey, Vijay K. Patel, Mehnaz Kamal, Talha Jawaid, Bapi Gorain, Prashant Kesharwani, Harish Rajak |
| 33 |
[GO] |
2021―Jun―24 |
Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective |
Amr Sonousi, Hanan A. Mahran, Ibrahim M. Ibrahim, Mohamed N. Ibrahim, Abdo A. Elfiky, Wael M. Elshemey |
| 34 |
[GO] |
2021―Jun―04 |
Use of glucocorticoids and azithromycin in the therapy of COVID-19 |
Miguel de Lemos Neto, Rafael Costa Vieira Alexandre, Rafaela Oliveira Gallart Morra, Juliana Aparecida Souza da Paz, Shana Priscila Coutinho Barroso, Angela Castro Resende, Daniel J. M. de Medeiros-Lima, Pedro Celso Braga Alexandre |
| 35 |
[GO] |
2021―May―10 |
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study |
Yamini Pathak, Amaresh Mishra, Gourav Choudhir, Anuj Kumar, Vishwas Tripathi |
| 36 |
[GO] |
2021―Apr―21 |
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective |
Seyed Hootan Hamidi, Sandhya Kadamboor Veethil, Seyedeh Harir Hamidi |
| 37 |
[GO] |
2021―Apr―11 |
Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis |
Raymond Pranata, Ian Huang, Sherly Lawrensia, Joshua Henrina, Michael Anthonius Lim, Antonia Anna Lukito, Raden Ayu Tuty Kuswardhani, I. Dewa Nyoman Wibawa |
| 38 |
[GO] |
2021―Mar―29 |
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis |
Chia Siang Kow, Hamid A. Merchant, Zia Ul Mustafa, Syed Shahzad Hasan |
| 39 |
[GO] |
2021―Mar―05 |
Perspectives on glucocorticoid treatment for COVID-19: a systematic review |
Leonardo P. Cordeiro, Eduarda O. N. N. Linhares, Fernanda G. O. Nogueira, Daniel Moreira-Silva, Daniel J. M. Medeiros-Lima |
| 40 |
[GO] |
2021―Feb―24 |
Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire |
Akif İşlek, Mustafa Koray Balcı |
| 41 |
[GO] |
2021―Feb―20 |
In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis |
Hikmat Permana, Ian Huang, Aga Purwiga, Nuraini Yasmin Kusumawardhani, Teddy Arnold Sihite, Erwan Martanto, Rudi Wisaksana, Nanny Natalia M. Soetedjo |
| 42 |
[GO] |
2021―Feb―19 |
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2 |
Albert Cortés-Borra, Gonzalo Emiliano Aranda-Abreu |
| 43 |
[GO] |
2021―Jan―03 |
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes |
Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, Phulen Sarma, Ajay Prakash, Bikash Medhi |
| 44 |
[GO] |
2021―Jan―03 |
SARS-CoV-2 therapeutics: how far do we stand from a remedy? |
Anurag Singh, Vandana Gupta |
| 45 |
[GO] |
2020―Nov―09 |
The effect of tocilizumab on cytokine release syndrome in COVID-19 patients |
Carmen de Cáceres, Rodrigo Martínez, Pablo Bachiller, Laura Marín, José Manuel García |
| 46 |
[GO] |
2020―Oct―28 |
Overview of the possible role of vitamin C in management of COVID-19 |
Anis Abobaker, Aboubaker Alzwi, Alsalheen Hamed A. Alraied |
| 47 |
[GO] |
2020―Oct―15 |
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis |
Krzysztof Marciniec, Artur Beberok, Paweł Pęcak, Stanisław Boryczka, Dorota Wrześniok |
| 48 |
[GO] |
2020―Oct―10 |
Observational study of people infected with SARS-Cov-2, treated with amantadine |
Gonzalo Emiliano Aranda-Abreu, José D. Aranda-Martínez, Ramiro Araújo, María Elena Hernández-Aguilar, Deissy Herrera-Covarrubias, Fausto Rojas-Durán |
| 49 |
[GO] |
2020―Sep―05 |
Drug repurposing approach to fight COVID-19 |
Thakur Uttam Singh, Subhashree Parida, Madhu Cholenahalli Lingaraju, Manickam Kesavan, Dinesh Kumar, Raj Kumar Singh |
| 50 |
[GO] |
2020―Aug―20 |
Pharmacological treatments of COVID-19 |
Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, Asal Tanzifi, Fatemeh Faramarzi, Reza Negarandeh, Mohammadreza Safdari, Masoud Khataminia, Hassan Rezai Ghaleno, Solomon Habtemariam, Amirhosein Khoshi |
| 51 |
[GO] |
2020―Jul―22 |
Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19 |
Moshe Rogosnitzky, Paul Okediji, Igor Koman |
|
